Research To Practice | Oncology Videos

Latest Episodes:

Desmoid Tumors | Practical Perspectives: Optimizing Diagnosis and Treatment for Patients with Desmoid Tumors Oct 18, 2024

Show notes

Featuring perspectives from Dr Thierry Alcindor and Dr Mrinal Gounder, including the following topics:

Introduction: Biology and Clinical Presentation (0:00)
Case: A man in his mid 60s with desmoid fibromatosis — Dr Alcindor (12:36)
Tyrosine Kinase Inhibitors (24:51)
Gamma Secretase Inhibitors (31:02)
Case: A woman in her early 40s with desmoid tumor treated with a gamma secretase inhibitor on a clinical trial — Dr Gounder (46:09)
Case: A woman in her late 30s with a large groin desmoid tumor — Dr Gounder (51:52)
Case: A woman in her early 30s with desmoid fibromatosis requiring treatment — Dr Alcindor (54:50)

CME information and select publications

Peripheral T-Cell Lymphoma | Oncology Today with Dr Neil Love: Peripheral T-Cell Lymphoma (Companion Faculty Lecture) Oct 17, 2024

Show notes

Featuring a slide presentation and related discussion from Dr Steven Horwitz, including the following topics:

Front-line management of peripheral T-cell lymphomas (PCTLs) (0:00)
Dose-intensified chemotherapy in combination with brentuximab vedotin for PTCL (9:59)
Role of CD30 for PTCLs (14:36)
Management of relapsed PTCL (20:40)

CME information and select publications

Peripheral T-Cell Lymphoma | Oncology Today with Dr Neil Love: Peripheral T-Cell Lymphoma Oct 17, 2024

Show notes

Featuring an interview with Dr Steven Horwitz, including the following topics:

Overview of peripheral T-cell lymphomas (PTCLs) (0:00)
Efficacy and safety of brentuximab vedotin in the management of treatment-naïve and relapsed PTCLs (9:57)
Emerging therapeutic strategies for PTCLs (19:48)
Case: A man in his early 50s with CD30-positive anaplastic large cell lymphoma who experienced complete response (CR) to BV-CHP and continued remission after consolidation with autologous stem cell transplant (ASCT) (25:53)
Management of ALK-positive anaplastic large cell lymphoma (32:14)
Case: A man in his late 50s with CD8-positive PTCL not otherwise specified who achieved CR with CHOEP and experienced relapse after ASCT (34:33)
Case: A woman in her early 70s with chemorefractory CD30-positive angioimmunoblastic T-cell lymphoma (38:26)
Ongoing first-line studies for T-cell lymphomas; association of CAR T-cell therapy with T-cell malignancies (42:18)

CME information and select publications

Metastatic Non-Small Cell Lung Cancer | The Implications of Recent Datasets for the Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer Oct 16, 2024

Show notes

Featuring perspectives from Dr Edward B Garon and Dr Luis Paz-Ares, including the following topics:

Introduction: Ivonescimab (0:00)
First-Line Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Tumor Mutation — Dr Garon (11:47)
Promising Therapeutic Strategies for Patients with Progressive Metastatic NSCLC — Dr Paz-Ares (42:01)

CME information and select publications

Chronic Lymphocytic Leukemia | Meet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 1 of a 3-Part Series Oct 10, 2024

Show notes

Featuring perspectives from Dr Matthew S Davids, including the following topics:

Introduction: Is Chronic Lymphocytic Leukemia (CLL) the New Chronic Myeloid Leukemia? Cases We Didn't Hear About Last Week (0:00)
Case: A man in his early 70s with IGHV-unmutated CLL (trisomy 12, del[17p]) receives ibrutinib for several years and is switched to acalabrutinib to lower the risk of cardiotoxicity — Warren S Brenner, MD (16:39)
Case: A man in his mid 70s with relapsed atypical del(17p) CLL who previously received ibrutinib receives venetoclax/obinutuzumab — Bhavana (Tina) Bhatnagar, DO (22:10)
Case: A woman in her early 80s with IGHV-mutated CLL begins treatment with zanubrutinib and 6 months later develops altered mental status due to cryptococcal meningitis — Erik Rupard, MD (33:00)
Case: A woman in her early 80s with relapsed CLL (del[17p]/TP53 mutation) develops Stevens-Johnson syndrome while receiving ibrutinib — Spencer H Bachow, MD (38:21)
Case: A man in his mid 90s with del(13q) CLL under observation for 12 years begins treatment with zanubrutinib and develops significant bruising/ecchymosis — Dr Rupard (41:14)
Case: A woman in her late 70s with relapsed del(13q) CLL receives acalabrutinib and develops hyperleukocytosis — Dr Bhatnagar (45:44)
Case: A woman in her mid 80s with rising white blood cell counts and asymptomatic recurrence of CLL (trisomy 12) receives rituximab with subsequent addition of venetoclax — Dr Brenner (50:20)
Transformed CLL; CAR T-Cell Therapy (53:38)
Journal Club with Dr Davids (54:26)

CME information and select publications

Diffuse Large B-Cell Lymphoma | Data + Perspectives: Clinical Investigators Discuss the Current and Future Management of Diffuse Large B-Cell Lymphoma Oct 09, 2024

Show notes

Featuring perspectives from Dr Christopher Flowers, Prof Grzegorz S Nowakowski and Dr Laurie H Sehn, moderated by Dr Flowers, including the following topics:

Introduction (0:00)
Front-Line Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Sehn (1:56)
Case: A woman in her late 40s with epidural DLBCL and a compression fracture (Dr Flowers) (12:45)
Case: A woman in her late teens with primary intestinal large B-cell lymphoma (Dr Nowakowski)(16:51)
Integration of Novel Agents into the Care of Patients with Relapsed/Refractory DLBCL — Dr Flowers (21:14)
Case: A man in his late 70s diagnosed with DLBCL with recurrent disease (Dr Nowakowski) (29:38)
Case: A woman in her mid 70s with multiple comorbidities diagnosed with DLBCL (Dr Sehn) (36:17)
Bispecific Antibody Therapy for DLBCL — Dr Nowakowski (39:39)
Case: A man in his late 50s with no comorbidities with recurrent DLBCL (Dr Sehn) (50:50)
Case: A patient in their mid 50s with DLBCL who experiences disease relapse after R-CHOP and CAR-T therapies (Dr Flowers) (54:34)

CME information and select publications

Non-Small Cell Lung Cancer with Actionable Targets Beyond EGFR | The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with Actionable Targets Beyond EGFR Oct 08, 2024

Show notes

Featuring perspectives from Dr Ibiayi Dagogo-Jack and Dr Corey J Langer, including the following topics:

Introduction: A Model for Targeted Treatment in Non-Small Cell Lung Cancer (NSCLC) (0:00)
NSCLC with ALK, ROS1 and NTRK Rearrangements — Dr Langer (9:10)
Current and Future Treatment of Metastatic NSCLC with RET, MET, HER2 and KRAS Alterations — Dr Dagogo-Jack (34:22)

CME information and select publications

Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | Data + Perspectives: Clinical Investigators Discuss the Role of CAR T-Cell Therapy for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Oct 04, 2024

Show notes

Featuring perspectives from Dr Joshua Brody, Dr Matthew Lunning and Dr Jason Westin, moderated by Dr Lunning, including the following topics:

Introduction (0:00)
Integration of Chimeric Antigen Receptor (CAR) T-Cell Therapy into the Management of Diffuse Large B-Cell Lymphoma — Dr Westin (1:34)
Current Role of CAR T-Cell Therapy for Other B-Cell Lymphomas — Dr Lunning (21:17)
Tolerability and Other Practical Considerations with CAR T-Cell Therapy — Dr Brody (40:15)

CME information and select publications

Non-Small Cell Lung Cancer with EGFR Mutations | The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with EGFR Mutations Oct 02, 2024

Show notes

Featuring perspectives from Dr Joshua K Sabari and Dr Helena Yu, including the following topics:

Introduction: Checkpoint Inhibitors and Lung Cancer with an EGFR Mutation (0:00)
Current Management of Metastatic Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutations — Dr Sabari (5:39)
Novel Therapeutic Approaches for NSCLC Harboring EGFR Mutations — Dr Yu (28:21)

CME information and select publications

Breast Cancer | Oncology Today with Dr Neil Love: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer (Companion Faculty Lecture) Sep 25, 2024

Show notes

Featuring a slide presentation and related discussion from Dr Tiffany A Traina, including the following topics:

Extended follow-up with pembrolizumab/chemotherapy for patients with previously untreated PD-L1-positive metastatic triple-negative breast cancer (mTNBC) (0:00)
ASCENT trial: Survival advantage with sacituzumab govitecan versus physician's choice of chemotherapy for patients with relapsed/refractory TNBC (2:49)
Treatment-associated side effects with sacituzumab govitecan (5:32)
Activity of sacituzumab govitecan irrespective of TROP2 expression level and in patients with brain metastases (6:48)
Ongoing Phase III studies evaluating sacituzumab govitecan in earlier lines of treatment (eg, ASCENT-03, ASCENT-04) (8:51)
Efficacy and tolerability of trastuzumab deruxtecan in patients with HER2-low and HER2-ultralow metastatic breast cancer (10:26)
Activity and ongoing investigations of other novel agents and strategies for mTNBC (20:05)

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Research To Practice | Oncology Videos

Related Podcasts

Links

Stay Connected